About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry. This is an ASCO ...

Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis. This is an ASCO ...

Or the melanoma was thicker than 4mm and not ulcerated stage 2C - this means it is thicker than 4 mm and is ulcerated You have an immunotherapy drug called pembrolizumab (Keytruda). A nurse gives it ...

A promising experimental blood test has shown the ability to accurately detect colon cancer with 81% accuracy in patients and correctly rule it out in 90% of healthy individuals. This less ...

The CheckMate 8HW trial is the first to compare single-agent immunotherapy to dual-agent immunotherapy in the first-line metastatic colorectal cancer setting. The trial included 582 patients who ...

We also explore the controversy surrounding CDK4/6 inhibitors in adjuvant breast cancer therapy and discuss the MARIPOSA data for ... has received FDA approval for the treatment of previously treated ...

This means further work is necessary to determine how best to use radiotherapy to maximise the benefits of other treatments, such as immunotherapy. For the first time, the researchers assessed this ...

“The current trial provides the only results on cancer immunotherapy plus chemotherapy as adjuvant-only treatment, and no other immunotherapy trials are investigating this specific therapeutic ...